A recent study has documented, in mice and humans carrying clonal hematopoiesis of indeterminate potential (CHIP)-mutations, that colchicine can blunt the higher risk of ASCVD associated with somatic TET2 mutation-driven CHIP by suppressing IL-1β overproduction [273]. This evidence concerns the gene IL1B and atherosclerosis.